Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer.
PSMA is basis for new diagnostics and theranostics. PET/CT using PSMA is more sensitive …

Purpose Preliminary data from retrospective analyses and recent data from large
randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) …

Purpose Up to 30% of patients with prostate-specific membrane antigen (PSMA)-positive
metastatic castration-resistant prostate cancer (mCRPC) never respond or develop …

This review paper highlights the transformative role of PSMA-targeted diagnostics and
therapy in prostate cancer management, particularly focusing on 177 Lu-PSMA-617 …

TPS180 Background: 177Lu‐PSMA-617 (Lu-PSMA) is a radiolabeled small-molecule that
binds with high affinity to PSMA enabling highly targeted delivery of beta radiation to …

Simple Summary Metastatic castration-resistant prostate cancer (mCRPC) with extensive
spread to the bone marrow is an incurable stage of disease associated with a poor …

Background The recent phase III VISION-trial confirms the treatment efficacy of radioligand
therapy with [177Lu] PSMA-617 (PSMA-RLT) in metastatic castration-resistant prostate …

Objective To assess the activity and safety of sequential lutetium‐177 (177Lu)‐PSMA‐617
and docetaxel vs docetaxel on a background of androgen deprivation therapy (ADT) in men …

Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …

Introduction The prostate-specific membrane antigen (PSMA) targeted radioligand therapy
(PRLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients …